News & Events
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis (opens in a new tab)
– Microbiome data demonstrate the successful engraftment of SER-287 – – Microbiome assessments suggest potential for biomarker-based patient selection – – Company continues to evaluate SER-287 study data, and available preliminary SER-301 Phase 1b study clinical and microbiome data, to inform plans…
Microba Life Sciences becomes first Australian microbiome company granted ISO15189 accreditation by NATA (opens in a new tab)
Microba receives ISO15189 accreditation for untargeted metagenomic assay of stool samples, unlocking diagnostic applications of the microbiome. The post Microba Life Sciences becomes first Australian microbiome company granted ISO15189 accreditation by NATA appeared first on Microba Life Sciences.…
Researchers to investigate the gut-brain axis in soldiers using Microba’s technology (opens in a new tab)
Leading Australian universities will explore the ‘cognobiome’ of soldiers using Microba’s analysis platform to discover opportunities for improving cognitive and physiological performance. The post Researchers to investigate the gut-brain axis in soldiers using Microba’s technology appeared first on Microba Life Scienc…
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD) (opens in a new tab)
– SER-155 is designed to reduce the incidence of infection, mortality and GvHD in adults undergoing hematopoietic stem cell transplantation (HSCT) – – Seres is collaborating with Memorial Sloan Kettering Cancer Center and The University of Chicago for the study – CAMBRIDGE, Mass.…
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 24, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , participated in a pre-recorded fireside chat as part of the Piper…
Results from collaborative Autism CRC study reveals new perspective on gut microbiome-autism link (opens in a new tab)
Results published in Cell show dietary restriction drives microbiome diversity changes in autistic individuals. The post Results from collaborative Autism CRC study reveals new perspective on gut microbiome-autism link appeared first on Microba Life Sciences.…
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates (opens in a new tab)
– Enrollment completed in SER-109 recurrent C. difficile infection open-label study – – Company expects both completed SER-109 Phase 3 study results and pending safety database to support finalization of Biologics License Application (BLA) filing in mid-2022 – – Collaboration with Bacthera A.G.…
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection (opens in a new tab)
BASEL, Switzerland & CAMBRIDGE, Mass. & HORSHOLM, Denmark –(BUSINESS WIRE)–Nov. 10, 2021– Bacthera, a specialized contract development and manufacturing organization (CDMO), and Seres Therapeutics , a leading microbiome therapeutics company, announced today a collaboration to manufacture…
Alveolus Bio Joins Microbiome Therapeutics Innovation Group (opens in a new tab)
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition […]…
Interim report January – September 2021 (opens in a new tab)
The post Interim report January – September 2021 appeared first on Genetic Analysis.…
Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 4, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 10, 2021 at 8:30 a.m.…
Genetic Analysis awarded important US patent covering a companion diagnostic method for optimising IBS interventions (opens in a new tab)
The post Genetic Analysis awarded important US patent covering a companion diagnostic method for optimising IBS interventions appeared first on Genetic Analysis.…
RBX2660, an Investigational Live Microbiota-based Biotherapeutic, Improves Outcomes of Clostridioides difficile Infection in a Real-World Population: A Retrospective Study of Use Under Enforcement Discretion (opens in a new tab)
Paul Feuerstadt1, Adam Harvey2, Lindy Bancke21Gastroenterology Center of Connecticut, Hamden, CT; 2Rebiotix Inc, a Ferring Company, Roseville, MN Background Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat. RBX2660 is a standardized, stabilized, investigational microbiota-based live…
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting (opens in a new tab)
– Study shows that SER-109 reduced the risk of recurrent C. difficile infection in patients with risk factors for recurrence, including acid-reducing medications – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 26, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company,…
Genetic Analysis enters a Service Agreement with Eurofins ADME BIOANALYSES – The first CRO to offer the GA-map® Microbiome test (opens in a new tab)
The post Genetic Analysis enters a Service Agreement with Eurofins ADME BIOANALYSES – The first CRO to offer the GA-map® Microbiome test appeared first on Genetic Analysis.…
Genetic Analysis receives important patent allowance in China (opens in a new tab)
OSLO, NORWAY – 14 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has been awarded an important patent (CN107430644A) by the China National Intellectual Property Agency (CNIPA). The patent entitled “A METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS” cov…
Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary (opens in a new tab)
Extensive legal experience with private and public biotech companies including Biogen, IVAX Corporation and Cell Signaling Technology CAMBRIDGE, MA, October 14, 2021 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today …
Microbiome Dx Genetic Analysis raises USD 6.8 M in IPO (opens in a new tab)
Closes up 50 % on first two days of trading as EU and US commercialisation drive of GA-map® platform begins OSLO, NORWAY – 5 October 2021: Microbiome DX company Genetic Analysis AS closed up 50% over the first two days of trading on the Swedish Spotlight Stock Market following completion of a share issue. The issue of …
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA (opens in a new tab)
High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo Represents most advanced clinical trial of a rationally defined bacterial consortium candidate BARDA ex…
Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies (opens in a new tab)
Lindy Bancke PharmD1, Xin Su MD1 1Rebiotix, Inc., a Ferring Company, Roseville, MN, USA Background Microbiota-based treatments have shown promise to reduce recurrence, morbidity, and mortality for recurrent Clostridioides difficile infections (rCDI), but consistent and reliable clinical efficacy data are needed to supp…